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inborn errors of metabolism (ieMs) are rare diseases produced by the accumulation of abnormal 
amounts of metabolites, toxic to the newborn. When not detected on time, they can lead to irreversible 
physiological and psychological sequels or even demise. Metabolomics has emerged as an efficient and 
powerful tool for ieM detection in newborns, children, and adults with late onset. in here, we screened 
urine samples from a large set of neonates (470 individuals) from a homogeneous population (Basque 
Country), for the identification of congenital metabolic diseases using NMR spectroscopy. Absolute 
quantification allowed to derive a probability function for up to 66 metabolites that adequately 
describes their normal concentration ranges in newborns from the Basque country. the absence of 
another 84 metabolites, considered abnormal, was routinely verified in the healthy newborn population 
and confirmed for all but 2 samples, of which one showed toxic concentrations of metabolites 
associated to ketosis and the other one a high trimethylamine concentration that strongly suggested an 
episode of trimethylaminuria. thus, a non-invasive and readily accessible urine sample contains enough 
information to assess the potential existence of a substantial number (>70) of IEMs in newborns, using 
a single, automated and standardized 1H- nMR-based analysis.
Inborn errors of metabolism (IEMs) are genetic disorders, usually monogenic disorders, that produce an abnor-
mal accumulation of metabolites due to a malfunctioning protein (i.e. an enzyme or a membrane transporter), 
involved in the intermediary metabolism. More than 1000 IEMs have been described so far1. While each of these 
disorders may be considered as a rare disease, in total they constitute a significant socio-economic burden with, 
for instance, an overall incidence of more than 1 in 1.000 affected newborns in Europe. If these diseases remain 
undetected and untreated, they can lead to irreversible physical and psychological sequels or even death. Thus, 
IEMs represent a serious public threat that involves intensive, long, and expensive treatments.
While some of these diseases may emerge only in later stages, with chronic and progressive symptoms, most 
of the neonates with IEMs will develop symptoms typically within hours or days after birth. In this context, an 
early diagnosis is crucial to adequately prescribe the right therapies to successfully treat these disorders which, in 
favorable cases, may grant patients a significantly improved quality of life.
Metabolomics is a powerful tool to study IEMs and, for decades, thousands of neonates have been diag-
nosed through different newborn screening programs. The standard newborn screening card based on blood 
spots taken from the heel, is routinely analyzed by conventional mass spectrometry2. More sophisticated 
MS-based techniques such as nanospray ionization with high resolution mass spectrometry (nS-HR-MS)3 or 
whole exome sequencing4,5 are also available, however they are much more time consuming and/or expensive. 
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NMR spectroscopy is well suited to characterize biofluids as it is a quantifiable, reproducible, non-selective and 
non-destructive and it is particularly adequate for the characterization of complex solutions (plasma, serum, 
urine, etc.)6–8, although is sensitivity is lower as compared to mass spectrometry. Consequently, NMR has already 
been applied to neonates with congenital metabolic diseases9,10. 1H-NMR spectroscopy successfully identified 
neonates carrying different inborn errors including phenylketonuria11, maple syrup urine disease12 and errors of 
purine and pyrimidine metabolism13.
In 2014 a group of Turkish hospitals carried out a 1H-NMR based clinical study where urine of more than 900 
newborns was analyzed to derive the normal concentration ranges for up to 20 normal metabolites and 45 patho-
logical metabolites involved in IEMs14. Here, we have implemented and expanded this methodology to conduct 
a clinical study on urine samples from 470 newborns, obtained from the four public hospitals with neonatology 
units in the Basque Country. Data analysis allowed to derive the normal metabolic profile of local newborns and 
to implement an automated screening routine to identify up to 75 congenital metabolic diseases that can be easily 
extrapolated to other geographical regions.
Results
Description of the data collection. Complete demographic data was collected for 470 neonates, except 
for two samples, with no pertaining metadata. After initial quality control, urine samples from 9 newborns were 
discarded because they showed centrifugation-resistant turbidity, a feature usually associated with bacterial con-
tamination. The final dataset was composed of 461 samples.
More than 50% of the urine samples were collected at 2–3 days age (Table S1) and all samples were obtained 
from newborns with a birth weight above 2.5 Kg. The dominant ethnic group is Caucasian (>80%) and males 
and females were equally represented in the study. Gestational age, head circumference and feeding type varied 
largely (Table S1).
1H-nMR spectra acquisition and multivariate analysis. Two different 1H-NMR spectra were col-
lected: a high-resolution 1D 1H spectrum yielded quantitative metabolite data for statistical analysis and a 2D-Jres 
experiment assisted in peak assignment and metabolite identification. All spectra were collected at 300 K under 
strict SOPs (see Material and Methods) on either a 600 MHz Bruker AVANCE III (244 samples) or AVANCE 
IVDr (213 samples) spectrometer, where neither PCA nor PLS analyses revealed any statistical difference between 
both subsets (Fig. S1).
The 1D 1HNMR spectra were then automatically processed and integrated over segments of 0.01 ppm spectral 
width to obtain bin intensities for statistical analysis. A visual comparison identified six urine samples with poor 
spectral quality and water suppression that were discarded from further analysis. Using multivariate analysis, 7% 
of the samples presented multiple regions of the spectra with deviations from normality (Fig. S2) and were no 
longer considered. This value is lower than previous equivalent studies11, and we attribute the discrepancy to the 
different number of engaged clinical partners and to an improved coordination with the hospitals.
For the remaining set of 437 urine samples, an initial PCA of bin intensities provided a first survey of the 
metabolomic data and unbiased rough sample clustering. Neither PCA nor PLS revealed any statistically sig-
nificant differences between sample subsets from the different hospitals (Fig. 1). Likewise, no correlation with 
other metadata was observed by PLS-DA except for gender and age at sample collection, for which a metabolic 
fingerprint is observed (Fig. S3) as reported previously14. A slight trend for clustering was observed as a function 
of head circumference (Fig. S3E), consistent with previous results15.
Figure 1. PLS-DA analysis of urine samples. Two-dimensional PLS-DA score plot for different hospitals. HB: 
Basurto Hospital, CRC: Cruces Hospital, HD: Donosti Hospital, TX: Txagorritxu Hospital.
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Targeted analysis: metabolite identification and quantification. Targeted analysis aims at quantify-
ing a given set of metabolites. To that end, the chemical information associated with the bins in the 1D 1H-NMR 
spectrum in combination with the multiplicity information extracted from the 2D J-resolved spectrum was com-
bined to identify up to 150 metabolites in the urine spectrum (Table S2). For each metabolite, the concentration 
was calculated both, absolute or relative to creatinine. Absolute quantification was referred to the TSP signal in 
the urine spectra, calculating a signal-intensity per-proton-ratio after the correction for several effects including 
molecular mass, number of protons, relaxation time, chemical shift, signal multiplicity and coupling constants, 
line width and Gauss–Lorentz ratio. To that end, signal was fitted using a simplex algorithm also looking for the 
ranges for signal detection and quantification. Quantification relative to creatinine (in mmol/mol creatinine) used 
the intensity ratio between a specified metabolite signal and the methyl signal of creatinine.
For a given metabolite, the limit of detection (LOD, Table S2) was determined via spiking experiments from 
an equivalently measured reference sample database and by simulating spectra after different concentrations of 
the analyte were added14. Averaging over the total cohort allows calculating the probability of obtaining a value 
above the LOD for the metabolite.
probabilistic models for the quantified metabolites. Of 150 metabolites considered, 58 always 
remained below their LOD (see Table S2) and where, therefore, never detected. Of the remaining 92 metabolites, 
66 had a detection incidence of 2.5% or more, allowing to fit a distribution model. As a metabolite’s LOD implies 
incomplete sampling of the underlying distribution with a natural skew towards higher metabolite concentra-
tions, a generalized extreme value (GEV) distribution model was chosen for its inherent adaptability16. GEV is a 
probability distribution based on extreme value analysis (i. e. extreme deviations from the median of probability 
distributions) and it seeks to assess the probability of extreme events such as the skewed distributions for the 
quantified metabolites that considers the LOD values.
Table S2 reports the derived distribution parameters for the 150 metabolites considered and the Q2.5 and 
Q97.5 quantiles (which delimit the range where 95% of samples are found) obtained from a GEV distribution 
model (calculated with Eq. 4) or directly from the data histogram. The quantile values obtained by both methods 
are in excellent agreement except for acetic acid, where the Q97.5 value from the GEV model (332) is larger than 
that from the data histogram (240) presumably due to the slightly more permissive ranges obtained with the 
model (Fig. S4).
Figure 2 shows 9 representative examples of metabolite concentration histograms along with modeled proba-
bility densities from a GEV distribution that fit well to the experimental data regardless of the detection frequency 
and the histogram shape (the data for all traceable 66 metabolites with a detection frequency larger than 2.5% 
is shown in Fig. S4). Thus, the protocol for model building presented here can be applied to derive the normal 
metabolite concentrations in newborn urine samples for the general population in the Basque Country and to 
reveal significant deviations as a strong indication for a genetic disorder associated to the pertaining metabolite.
Diagnostic value of the investigated metabolites. Out of the 150 metabolites determined in the urine 
samples (Table S2), 7 derive from contaminations from the matrix used (diaper and the plastic consumables), 
Figure 2. Example of probability densities from 9 representative GEV models. Densities calculated from 
models are represented as black lines with the following legend: dotted for low, dashed for intermediate and 
solid for high percentage of detection for the metabolite. Light blue bars plot experimental real data, where 
values below LOD were discarded.
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19 metabolites are associated with bacterial contamination, likely during the sample collection, 14 metabolites 
derive from drug catabolism (active principles or excipients) and 12 metabolites are associated to the mother’s 
diet (i. e. caffeine). These metabolites contain little diagnostic nor therapeutic information, but provide metadata 
information and potential insight on the bacterial gut microbiota of the newborn.
The remaining set of 98 relevant metabolites have been associated with inborn errors of metabolism (IEMs) 
and, therefore, have potential diagnostic value for the 75 diseases and unhealthy conditions summarized in 
Table 1. The metabolites are numbered as shown in Table S2. Most commonly, an IEM produces alterations for 
several metabolites where the “reference metabolites” listed in Table 1 are those required to unambiguously iden-
tify an IEM, according to the seminal work of Wevers17 and others18. Yet, as many metabolites can show abnormal 
concentrations due to different IEMs, their specific range values (if available, e.g., from HMBD, Metagene) are 
reported in Table S2. These “support metabolites” are also related to a disorder and can, thus, further confirm an 
IEM or help to differentiate between related IEMs. Finally, for metabolites that occur in the urine of both healthy 
and IEM affected newborns, the modeled GEV distributions can be used to determine the probability for our 1H 
NMR based test to indicate a potential IEM case in the Basque Country (Fglobal listed in Table 1). Such value cor-
responds to the frequency probability of finding a newborn with a concentration above the pathogenic threshold 
value. In cases where more than one metabolite showed up with a diagnostic distribution for a given IEM, the 
larger value of Fglobal was used for indication.
Metabolic disorders detected within the cohort. In at least two newborn urine samples, we found 
abnormal concentrations of metabolites related to an alteration in the ketonic bodies. The first sample showed 
concentrations of 3-hydroxybutyric acid (240 mmol/mol creat), acetone, (210 mmol/mol creat), and acetoacetic 
acid (62 mmol/mol creat) far above their upper limits derived from the modeled distributions, with probabilities 
of 0.002, 0.0012, and <0.0001, respectively. Moreover, these metabolite concentrations were also higher than 
states as normal in metabolomics databases (HMDB, Metagene). The second sample likewise showed abnor-
mally high concentrations for 3-hydroxybutyric acid (170 mmol/mol creat, probability 0.0124) and acetoacetic 
acid (49 mmol/mol creat, probability 0.0004), which were accompanied by an elevated glucose concentration 
(560 mmol/mol creat, probability 0.0083). Taken together, these experimental results strongly suggest two cases 
of ketosis that might be related to a transition state of the newborn.
Finally, a third newborn presented high levels of trimethylamine (24 mmol/mol creatinine; probability 0.0014) 
suggesting the IEM Trimethylaminuria (FMO3) since the normal concentrations in newborns, as determined in 
our 1H NMR study (Fig. 2), are not higher than 6 mmol/mol creat. Yet, this finding should be accompanied by 
elevated concentrations TMAO, currently unavailable within our method.
Discussion
In this contribution we have investigated novel strategies for an early identification of congenital metabolopathies 
from 1H NMR data from newborn urine samples. Even though IEMs are individually considered as rare disor-
ders, their collective incidence is considerable and represents a serious public health problem. An early diagnosis 
of these pathologies is crucial to avoid serious acute symptoms and/or to avoid a lifelong treatment of patients. 
In the context of personalized medicine, even a negative (unsuspicious) result of such IEM tests still produces 
relevant data that can be integrated in a personal database together with molecular data which is expected to gain 
diagnostic value in the future.
In the last years had been increasing the number of IEM (around 50) that can be detected using mass spec-
trometry19, even though that the high sensitivity of the technique suggests that this number will increase. 
Moreover, MS requires the collection of dried blood spots (DBS), which is done by pricking the heel of newborns. 
It is easy to perform but the process is in a certain way invasive. In NMR spectroscopy, currently 75 IEMs may 
be detected and this number is also increasing over time. In here, up to 1000 urine metabolites are analyzed 
simultaneously in a measurement that avoids pricking and takes only minutes. In summary, compared to other 
techniques such as MS, NMR spectroscopy has great potential for newborn screening, as it is able to sample 
the metabolic profile and detect both known and unknown metabolites in a quantitative and non-targeted way. 
Moreover, it is reproducible, and the quantification of urine metabolites is independent on the instrument con-
figuration as long as the SOPs are followed. Finally, the measurement is economically advantageous since the 
comprehensive metabolite set is already obtained. All these aspects position the technique in a leading place for a 
potential implementation of the methodology in hospitals and health centers for the screening of large population 
segments.
Using the metabolomics data provided from the whole cohort of newborns along with statistical analysis, 
we were able to create a healthy metabolome profile at a high degree of precision. A subset of 66 of the analyzed 
metabolites were found present in at least 2.5% of all the newborns. Normal ranges for these common metabolites 
have been established using automatic quantification, as shown in Figs S4–S6, and Table S2, also compared to the 
normal and pathogenic levels reported in the literature. Some metabolites showing close proximity (or partial 
overlap) between normal and pathogenic concentrations reflect a heterogenic origin for the metabolite or an 
incomplete understanding of the relationship between the metabolite and the disease.
IEM incidence strongly depends on geographical and ethnic background of a population20 and it is instructive 
to compare our model with the Turkish model previously reported14. The metabolites found in our study enclose 
18 out of the 20 found in the Turkish work, while myo-Inositol and trimethylamine are found very often only 
in the Turkey model. We attribute such discrepancy to an improved identification of the two metabolites in our 
deconvolution algorithm.
Another 84 metabolites that are typically not found at NMR detectable level in healthy newborns were vali-
dated for their absence. Finally, we were also able to observe metabolites from different sources of contamination. 
Propylene glycol was present in about half of the urine samples likely from external manipulation. This aliphatic 
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IEM
Reference 
metabolites
Support 
Metabolites Fglobal
Organic Acidurias
2-ketoadipic acidemia 80, 105, 135 1,82e-6
3-Hydroxy-3-Methylglutaryl-CoA-lyase Deficiency 17, 20, 25 24, 38, 84 1.74e-04
3-Hydroxyisobutiric aciduria 8, 20, 21, 102 n. a.
3-Methyl-crotonyl-glycinuria 20, 24 13 1.61e-3
3-Methyl-glutaconic acidurias 20, 25, 103 54, 132, 135 1.58e-2
Biotinidase deficiency 20, 24, 102 21 2.90e-2
β-Ketothiolase deficiency 25, 143 18, 20, 21, 24, 38 >7.14e-2
Canavan disease 110 135 >7.14e-4
Cobalamin malabsortion 108 4.13e-6
Ethylmalonic encephalopathy 43, 78, 80, 102, 135 12, 114 2.34e-3
Fumaric aciduria 80, 135 7.14e-4
Glutaric aciduria type I 19, 76, 84 18 5.38e-3
Glutaric aciduria type I (low excretor) 19, 76, 84 5.38e-3
Glutaric aciduria type I (non-excretor) 19, 76 n. a.
Glutaric aciduria type II 12, 78, 84, 92 19, 76, 114, 134 2.34e-3
Glutaric aciduria type II (late onset) 20, 78, 84 2.34e-3
Glutaric aciduria type III 84 n.a.
Hyperoxaluria type II 87 >3.09e-1
Isovaleric aciduria 20, 114 12, 18, 86, 108 n. a.
Malonyl-CoA decarboxylase deficiency 78, 108, 135 7.14e-4
Methylmalonic aciduria 16, 75, 91, 129 3.19e-2
Methylmalonate semialdehyde dehydrogenase deficiency 21, 43, 102, 108 2.00e-4
MMA Cbl A deficiency 108 22, 86, 89, 99 4.13e-6
Propionic acidemia 18, 21, 38, 40, 143
3, 22, 86, 89, 
99, 128, 129 6.66e-2
Pyroglutamic acidemia 99 n. a.
Transcobalamin II deficiency 108 n. a.
Trimethylaminuria 145 4.25e-3
Amino Acidurias
Argininemia 117, 147 88, 89 4.67e-3
Argininosuccinic aciduria 47, 117, 147 86, 89 4.37e-3
Cystinuria 46, 58 4.01e-5
Dicarboxylic aminoaciduria 82 n. a.
Dimethylglycine dehydrogenase deficiency 49, 115 5.91e-12
Hartnup disease 43, 83, 98, 103, 149 75, 101 4.39e-4
Hawkinsinuria 32, 99 8.54e-2
Holocarboxylase syntetase deficiency 20, 21, 22 2.07e-1
Homocystinuria 97 49, 107 n.a.
Kyneureninase deficiency 74, 150 n. a.
Maple Sirup Urine disease 9, 15, 23 3, 8, 14, 18, 98, 103, 149 8.46e-8
Methionine malabsortion 11 n. a.
Mild Phenylketonuria 116, 124 n. a.
Phenylketonuria 10, 26, 32, 112, 123, 124, 125 37, 65 n. a.
Saccharopinuria 55 n. a.
Sarcosinemia 134 4.56e-1
Tyrosinemia type I 31, 32, 33, 75, 136 35, 113, 147 5.83e-3
Tyrosinemia type II 31, 33 113 3.51e-2
Tyrosinemia type III 31, 32, 33 >7.62e-2
Transient newborn tyrosinemia 31, 33 3.51e-2
Valinemia 149 4.39e-4
Fatty Acid Oxidation Disorders
Continued
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alcohol is a chemical included in cosmetics, skin conditioning also found in medication21. Moreover, the metabo-
lite acetoin (present in perfumes) was observed in a few spectra from the same hospital (Fig. S2), while unknown 
metabolites could be detected in a subset of the spectra as well. A future goal is to proceed with the identification 
of unknown peaks, to determine whether they contain potentially diagnostic information.
Deviations from normality in some of those common metabolites provide very useful information about rare 
and prevalent metabolic disorders. Up to 75 IEMs may potentially be detected based on the quantification of a 
single metabolite or the combination of several of them (Table 1). Such disorders can be divided into urea cycle 
disorders, organic acidurias, purine/pyrimidine disorders, amino acidurias, carbohydrate disorders, creatine defi-
ciencies, fatty acid oxidation disorders and other diseases and syndromes. For example, elevated concentrations 
of 3-hydroxybutyric acid, acetone and acetoacetic acid revealed a couple of ketosis cases (Fig. 3). Ketosis is a 
metabolic state where the newborns use fat as fuel in preference to carbohydrates. The body makes ketones from 
fat, when dietary glucose (from carbohydrates and sugar) is low. Acetoacetate is one of the products of fatty acid 
oxidation and acetone and hydroxybutyrate are formed from acetoacetate22. In one case, the metabolic alteration 
was accompanied by high levels of glucose, an indicator of Insuline-dependant diabetes Mellitus. In another 
unrelated sample, a case of trimethylaminuria was also potentially identified. Hence, this approach has proven 
very useful for the discrimination of pathological samples by identifying abnormal metabolite concentrations or 
IEM
Reference 
metabolites
Support 
Metabolites Fglobal
3-Oxoacid CoA transferase deficiency 18, 38 5.38e-3
Long Chain 3-hydroxyacyl-CoA dehydrogenase 
deficiency 18 6.66e-2
Short Chain Acyl-CoA dehydrogenase deficiency 12, 78 4.92e-5
Short Chain 3-hydroxyacyl-CoA dehydrogenase 
deficiency 18 6.66e-2
Urea Cycle Disorders
Carbamoyl Phosphate synthetase I deficiency 86, 99, 147 4.37e-3
Citrullinemia 55, 117, 147, 148 47, 61, 89 3.47e-1
Neonatal intrahepatic cholestasis 32 n. a.
Ornitine carbamoyltransferase deficiency 117, 147, 148 86, 89, 99 4.67e-3
Creatine Deficiencies
Creatine transport deficiency 56, 57 n. a.
Guanidinoacetate Methyltransferase deficiency 88 n. a.
Purine/Pyrimidine Disorders
Dihydropyrimidine Dehydrogenase deficiency 141, 147 4.37e-3
Dihydropyriminidase deficiency 70, 71 141, 146, 147 4.37e-3
Orotic aciduria 117 n. a.
Carbohydrate Disorders
Fructose-1,6-bisphosphatase Deficiency 18, 38, 40 85 >7.14e-2
Fanconi-Bickel syndrome 63 61, 81 >3.47e-1
Galactosemia 61, 81 60 3.47e-1
Lysosomal Disorders
Tay-Sachs disease 99 n. a.
Mitochondrial Disorders
Dihydrolipoyl dehydrogenase E3 14, 23 2.29e-4
Lactic acidemia 43, 102 21 2.9e-2
Pyruvate carboxylase deficiency 18, 40, 102 43, 135 5.38e-3
Porphyrias
Acute Intermittent Porphyria 35 1.49e-5
Delta-aminolevulinic acid dehydratese deficiency 35 1.49e-5
Other Disorders
Asphyxia 23, 102 4.03e-2
Aminoacylase I deficiency 111 n. a.
GABA transaminase deficiency 27, 55 >1.24e-1
Molybdenum cofactor deficiency 139 1.42e-2
Ketosis 18, 38 6.66e-2
Table 1. IEMs that can be associated to the NMR-based urine analysis. List of different inborn errors of 
metabolism that can be identified by NMR. Reference metabolites are required to unambiguously identify a 
given IEM. Support Metabolites add value to confirm a specific IEM and/or help to discriminate between 
related IEMs. All numbers are related to the metabolites listed in Table S2. Fglobal describes the probability for the 
test to identify a potential IEM case in the Basque Country.
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patterns after comparison with the model. Unfortunately, the samples were codified and anonymized so clinicians 
did not have the opportunity to follow the babies that showed these abnormal metabolites.
The number of samples analyzed constitute a limitation in our study: approximately 1:1000 neonates may be 
affected by a congenital metabolic disorder worldwide. In this context, analyzing less than 500 samples, we were 
able to detect up to three different metabolopathies, showing the method’s potential. Yet, a higher number of 
samples will be needed to further validate the analytical technique.
In summary, the characterization of a large set of samples prompted us to develop a statistical model for 
several metabolites applicable to the healthy Basque Country newborn population. The model allows the iden-
tification of 75 different IEMs based on the comparative analysis of the absolute concentration of metabolites 
from a test sample in the context of the normal values obtained by the model which, in correlation with clinical 
parameters, allows the diagnosis and eventually the monitoring of patients throughout their illness23. The reason-
able agreement with the number of metabolites and the concentration ranges found in other regions (i. e. Turkey) 
underline the idea that the model can be easily extrapolated to multiple regions, ultimately constituting a reliable 
alternative to the heel test for IEMs premature detection.
Methods
Study design. Urine samples were collected from 470 individuals that were born in one of the four pub-
lic hospitals of the Basque Country with neonatology units: Cruces (Barakaldo, Bizkaia), Txagorritxu (Vitoria, 
Araba), Basurto (Bilbao, Bizkaia) & Donostia (Donostia, Guipuzkoa). All samples were codified and anonymized 
to protect the confidentiality of individual participants.
nMR measurements. For each sample, a one-dimensional (1D) 1H-NMR spectrum with water peak sup-
pression24, and a 2D Jres experiment were collected at 300 K, using the Standard Operating Procedures described 
in the Supplementary Materials and Methods.
Statistical analysis. Outliers were properly identified and eliminated from the dataset. Multivariate and 
univariate statistics was applied to the dataset as explained in the Supplementary Materials and Methods.
Generalized extreme value distributions. The GEV distributions can be described by three parameters 
(location μ, scale σ, and shape ξ) and provide different levels of information. As usual in probability distributions, 
the cumulative distribution function (CDF) gives the probability of obtaining a value (concentration in this case) 
that is lower or equal than a specific threshold x. The CDF (FGEV) for a GEV distribution can be calculated accord-
ing to the following expression
Figure 3. Newborn diseases identify by NMR metabolomics. (A) Three different markers (3OH-butyric 
acid, acetoacetic acid and acetone) in an NMR spectrum of a urine sample from a newborn, show high 
concentrations as compared to the normal ranges of intensity for other urine samples, suggesting ketosis. (B) 
The metabolite trimethylamine shows also an extremely high concentration in one sample, strongly indicating 
the presence of trimethylaminuria for that neonate.
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

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
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s
( ; ) exp( (1 ) ) 0
exp( exp( )) 0 (1)
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1/
where s is the scaled value of x (s = (x − μ)/σ). Similarly, it is possible to calculate the probability of obtaining a 
concentration higher than x using the complementary CDF ( = −F F1GEV GEV). Due to LOD, FGEV was in fact 
incomplete because the fraction of samples below LOD had to be considered and the global CDF (Fglobal) was 
calculated with the following expression
λ λ ξ= − +F F s(1 ) ( ; ) (2)global GEV
where λ is the fraction of samples above LOD. From this expression is straightforward to deduce that
λ ξ=F F s( ; ) (3)global GEV
Moreover, since the CDF is invertible it is also possible to calculate specific concentrations associated to quan-
tiles using function QGEV, as shown in Eq. 4:
µ σ ξ µ σ ξ ξ ξ
µ σ ξ
=




+ − − > ∈ < ∈
− − = ∈
ξ−
Q p p p p
p p
( ; , , ) (( log( )) 1)/ 0 and [0, 1); 0 and (0, 1]
log( log( )) 0, (0, 1), (4)
where p is the quantile for which is wanted to obtain its associated concentration. It is also affected by incomplete-
ness of CDF due to LOD. For this reason, quantile q must be adjusted as follows:
λ
λ
′ =
− −p p (1 )
(5)
where the numerator calculates the amount of quantile p that is not covered by the fraction below LOD (1 − λ) 
and the numerator scales this result in the context of the modeled GEV.
ethical approval. All procedures followed were in accordance with the Helsinki Declaration of 1975 and 
under the guidance of the Good Clinical Practice (GCP). The study was approved by the Basque Country’s 
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